Joshua M. Bauml, MD, Perelman School of Medicine

Articles

Current and Future Use of MET Inhibitors in NSCLC

April 26th 2021

Healthcare professionals who manage patients with non–small cell lung cancer comment on their current experience using MET inhibitors as treatment for patients who harbor MET exon 14 skipping mutations and highlight strategies under investigation that will hopefully address current gaps in therapy.

MET Inhibitors in NSCLC: Mechanisms of Resistance

April 26th 2021

The rationale for using MET inhibitors as first-line therapy for patients with non–small cell lung cancer who harbor MET exon 14 skipping mutations and considerations for sequencing later lines of therapy based on what is known to date about mechanisms of resistance to MET inhibitors.

CNS Response to MET Inhibition in NSCLC

April 12th 2021

The significance of using MET inhibitors to manage patients who have MET exon 14 skipping mutations in non–small cell lung cancer with CNS (central nervous system) involvement.

Tepotinib for MET Exon 14 Skipping Mutations in NSCLC

April 12th 2021

Implications for treating patients with non–small cell lung cancer who harbor MET exon 14 skipping mutations with tepotinib, a MET inhibitor, based on data revealed by the VISION trial.

Capmatinib for MET Exon 14-Mutated NSCLC

April 5th 2021

Discussion on the FDA approval of capmatinib, a MET inhibitor, as treatment for patients with MET exon 14-mutated non–small cell lung cancer based on data demonstrated by the GEOMETRY mono-1 study.

Testing to Identify MET Exon 14 Mutations in NSCLC 

April 5th 2021

Recommendations for using next-generations sequencing panels as well as liquid biopsies to help identify MET exon 14 skipping mutations and other oncogenic drivers in patients with non–small cell lung cancer.

Updates on I/O Therapy for Non-Driver mNSCLC

September 1st 2020

EGFR Exon 20 Mutations in NSCLC

September 1st 2020

KRAS-Mutant NSCLC

September 1st 2020

HER2 Targeted Therapy for Treatment of NSCLC

September 1st 2020

MET Exon 14 Mutations in mNSCLC

September 1st 2020

RET Fusion+ mNSCLC

September 1st 2020

Dr. Joshua M. Bauml on the Impact of Pembrolizumab in Head and Neck Cancer

September 2nd 2016

Dr. Joshua M. Bauml on Pembrolizumab Versus Chemo in Head and Neck Cancers

August 16th 2016

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the differences between pembrolizumab (Keytruda) and cytotoxic chemotherapies.

Dr. Bauml on KEYNOTE-055 Study for Patients With HNSCC

June 30th 2016

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the preliminary results of the KEYNOTE-055 study, which investigated pembrolizumab (Keytruda) after failure on platinum-based therapy and cetuximab in patients with head and neck squamous cell carcinoma.

Dr. Bauml on a New Platform to Enhance Lung Cancer Clinical Trial Enrollment

September 9th 2015

Joshua M. Bauml, MD, assistant professor, University of Pennsylvania, discusses a novel IT platform designed to enhance lung cancer clinical trial enrollment.